B7-H3 in Cancer Immunotherapy—Prospects and Challenges: A Review of the Literature

In today’s oncology, immunotherapy arises as a potent complement for conventional cancer treatment, allowing for obtaining better patient outcomes. B7-H3 (CD276) is a member of the B7 protein family, which emerged as an attractive target for the treatment of various tumors. The molecule modulates an...

Full description

Saved in:
Bibliographic Details
Published inCells (Basel, Switzerland) Vol. 14; no. 15; p. 1209
Main Authors Mielcarska, Sylwia, Kot, Anna, Dawidowicz, Miriam, Kula, Agnieszka, Sobków, Piotr, Kłaczka, Daria, Waniczek, Dariusz, Świętochowska, Elżbieta
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 06.08.2025
MDPI
Subjects
Animals
B7 Antigens - immunology
B7 Antigens - metabolism
B7-H3 (CD276)
B7-H3 clinical trials
Biological products
Brain cancer
Brain tumors
Cancer
Cancer immunotherapy
Cancer therapies
Care and treatment
Cell growth
Clinical trials
Colorectal cancer
Cytokines
Cytotoxicity
Dendritic cells
Development and progression
Glioblastoma
Gliomas
Humans
immune checkpoint
Immune checkpoint inhibitors
Immune response
Immunology
Immunotherapy
Immunotherapy - methods
Literature reviews
Lung cancer
Lymphocytes
Lymphocytes T
Malignancy
Melanoma
Molecular modelling
Monoclonal antibodies
Neoplasia
Neoplasms - immunology
Neoplasms - therapy
Neuroblastoma
Neuroblasts
Patients
Pituitary
Prognosis
Prostate cancer
Review
solid tumors
Squamous cell carcinoma
T cells
Transcription factors
Tumor necrosis factor-TNF
Tumorigenesis
Tumors
New Brunswick
B7-H3 (CD276)
solid tumors
immune checkpoint
B7-H3 clinical trials
Online AccessGet full text

Cover

Abstract In today’s oncology, immunotherapy arises as a potent complement for conventional cancer treatment, allowing for obtaining better patient outcomes. B7-H3 (CD276) is a member of the B7 protein family, which emerged as an attractive target for the treatment of various tumors. The molecule modulates anti-cancer immune responses, acting through diverse signaling pathways and cell populations. It has been implicated in the pathogenesis of numerous malignancies, including melanoma, gliomas, lung cancer, gynecological cancers, renal cancer, gastrointestinal tumors, and others, fostering the immunosuppressive environment and marking worse prognosis for the patients. B7-H3 targeting therapies, such as monoclonal antibodies, antibody–drug conjugates, and CAR T-cells, present promising results in preclinical studies and are the subject of ongoing clinical trials. CAR-T therapies against B7-H3 have demonstrated utility in malignancies such as melanoma, glioblastoma, prostate cancer, and RCC. Moreover, ADCs targeting B7-H3 exerted cytotoxic effects on glioblastoma, neuroblastoma cells, prostate cancer, and craniopharyngioma models. B7-H3-targeting also delivers promising results in combined therapies, enhancing the response to other immune checkpoint inhibitors and giving hope for the development of approaches with minimized adverse effects. However, the strategies of B7-H3 blocking deliver substantial challenges, such as poorly understood molecular mechanisms behind B7-H3 protumor properties or therapy toxicity. In this review, we discuss B7-H3’s role in modulating immune responses, its significance for various malignancies, and clinical trials evaluating anti-B7-H3 immunotherapeutic strategies, focusing on the clinical potential of the molecule.
AbstractList In today’s oncology, immunotherapy arises as a potent complement for conventional cancer treatment, allowing for obtaining better patient outcomes. B7-H3 (CD276) is a member of the B7 protein family, which emerged as an attractive target for the treatment of various tumors. The molecule modulates anti-cancer immune responses, acting through diverse signaling pathways and cell populations. It has been implicated in the pathogenesis of numerous malignancies, including melanoma, gliomas, lung cancer, gynecological cancers, renal cancer, gastrointestinal tumors, and others, fostering the immunosuppressive environment and marking worse prognosis for the patients. B7-H3 targeting therapies, such as monoclonal antibodies, antibody–drug conjugates, and CAR T-cells, present promising results in preclinical studies and are the subject of ongoing clinical trials. CAR-T therapies against B7-H3 have demonstrated utility in malignancies such as melanoma, glioblastoma, prostate cancer, and RCC. Moreover, ADCs targeting B7-H3 exerted cytotoxic effects on glioblastoma, neuroblastoma cells, prostate cancer, and craniopharyngioma models. B7-H3-targeting also delivers promising results in combined therapies, enhancing the response to other immune checkpoint inhibitors and giving hope for the development of approaches with minimized adverse effects. However, the strategies of B7-H3 blocking deliver substantial challenges, such as poorly understood molecular mechanisms behind B7-H3 protumor properties or therapy toxicity. In this review, we discuss B7-H3’s role in modulating immune responses, its significance for various malignancies, and clinical trials evaluating anti-B7-H3 immunotherapeutic strategies, focusing on the clinical potential of the molecule.
In today's oncology, immunotherapy arises as a potent complement for conventional cancer treatment, allowing for obtaining better patient outcomes. B7-H3 (CD276) is a member of the B7 protein family, which emerged as an attractive target for the treatment of various tumors. The molecule modulates anti-cancer immune responses, acting through diverse signaling pathways and cell populations. It has been implicated in the pathogenesis of numerous malignancies, including melanoma, gliomas, lung cancer, gynecological cancers, renal cancer, gastrointestinal tumors, and others, fostering the immunosuppressive environment and marking worse prognosis for the patients. B7-H3 targeting therapies, such as monoclonal antibodies, antibody-drug conjugates, and CAR T-cells, present promising results in preclinical studies and are the subject of ongoing clinical trials. CAR-T therapies against B7-H3 have demonstrated utility in malignancies such as melanoma, glioblastoma, prostate cancer, and RCC. Moreover, ADCs targeting B7-H3 exerted cytotoxic effects on glioblastoma, neuroblastoma cells, prostate cancer, and craniopharyngioma models. B7-H3-targeting also delivers promising results in combined therapies, enhancing the response to other immune checkpoint inhibitors and giving hope for the development of approaches with minimized adverse effects. However, the strategies of B7-H3 blocking deliver substantial challenges, such as poorly understood molecular mechanisms behind B7-H3 protumor properties or therapy toxicity. In this review, we discuss B7-H3's role in modulating immune responses, its significance for various malignancies, and clinical trials evaluating anti-B7-H3 immunotherapeutic strategies, focusing on the clinical potential of the molecule.In today's oncology, immunotherapy arises as a potent complement for conventional cancer treatment, allowing for obtaining better patient outcomes. B7-H3 (CD276) is a member of the B7 protein family, which emerged as an attractive target for the treatment of various tumors. The molecule modulates anti-cancer immune responses, acting through diverse signaling pathways and cell populations. It has been implicated in the pathogenesis of numerous malignancies, including melanoma, gliomas, lung cancer, gynecological cancers, renal cancer, gastrointestinal tumors, and others, fostering the immunosuppressive environment and marking worse prognosis for the patients. B7-H3 targeting therapies, such as monoclonal antibodies, antibody-drug conjugates, and CAR T-cells, present promising results in preclinical studies and are the subject of ongoing clinical trials. CAR-T therapies against B7-H3 have demonstrated utility in malignancies such as melanoma, glioblastoma, prostate cancer, and RCC. Moreover, ADCs targeting B7-H3 exerted cytotoxic effects on glioblastoma, neuroblastoma cells, prostate cancer, and craniopharyngioma models. B7-H3-targeting also delivers promising results in combined therapies, enhancing the response to other immune checkpoint inhibitors and giving hope for the development of approaches with minimized adverse effects. However, the strategies of B7-H3 blocking deliver substantial challenges, such as poorly understood molecular mechanisms behind B7-H3 protumor properties or therapy toxicity. In this review, we discuss B7-H3's role in modulating immune responses, its significance for various malignancies, and clinical trials evaluating anti-B7-H3 immunotherapeutic strategies, focusing on the clinical potential of the molecule.
Audience Academic
Author Sobków, Piotr
Mielcarska, Sylwia
Dawidowicz, Miriam
Kłaczka, Daria
Waniczek, Dariusz
Świętochowska, Elżbieta
Kot, Anna
Kula, Agnieszka
AuthorAffiliation 2 Department of Oncological Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-514 Katowice, Poland; d201069@365.sum.edu.pl (M.D.); d201070@365.sum.edu.pl (A.K.); dwaniczek@sum.edu.pl (D.W.)
1 Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 19 Jordana St., 41-800 Zabrze, Poland; s85876@365.sum.edu.pl (A.K.); s86196@365.sum.edu.pl (P.S.); s73707@365.sum.edu.pl (D.K.)
AuthorAffiliation_xml – name: 2 Department of Oncological Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-514 Katowice, Poland; d201069@365.sum.edu.pl (M.D.); d201070@365.sum.edu.pl (A.K.); dwaniczek@sum.edu.pl (D.W.)
– name: 1 Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 19 Jordana St., 41-800 Zabrze, Poland; s85876@365.sum.edu.pl (A.K.); s86196@365.sum.edu.pl (P.S.); s73707@365.sum.edu.pl (D.K.)
Author_xml – sequence: 1
  givenname: Sylwia
  surname: Mielcarska
  fullname: Mielcarska, Sylwia
– sequence: 2
  givenname: Anna
  surname: Kot
  fullname: Kot, Anna
– sequence: 3
  givenname: Miriam
  surname: Dawidowicz
  fullname: Dawidowicz, Miriam
– sequence: 4
  givenname: Agnieszka
  surname: Kula
  fullname: Kula, Agnieszka
– sequence: 5
  givenname: Piotr
  surname: Sobków
  fullname: Sobków, Piotr
– sequence: 6
  givenname: Daria
  surname: Kłaczka
  fullname: Kłaczka, Daria
– sequence: 7
  givenname: Dariusz
  orcidid: 0000-0002-0410-8604
  surname: Waniczek
  fullname: Waniczek, Dariusz
– sequence: 8
  givenname: Elżbieta
  surname: Świętochowska
  fullname: Świętochowska, Elżbieta
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40801642$$D View this record in MEDLINE/PubMed
BookMark eNptks9uEzEQxleoiJbSI1e0EhcuW_xvNzYXFKJCI0UCoXK2JvZs4mjXDvZuUW88RJ-QJ8FpSmkQ9sHW-Def_XnmeXHkg8eieEnJOeeKvDXYdYkKWlNG1JPihJEJr4Qg6ujR_rg4S2lD8pC0oaR-VhwLIgltBDsprj5MqkteOl_OwBuM5bzvRx-GNUbY3vz6efslhrRFM6QSvC1na-g69CtM78pp-RWvHf4oQ1tmvly4IScNY8QXxdMWuoRn9-tp8e3jxdXsslp8_jSfTReVEYypikmFDEFyIlQ7wdYoUIoLUytCEaxqVCOosTXkuFRApFxmP2xZ09a0FBU_LeZ7XRtgo7fR9RBvdACn7wIhrjTEwZkOtV0KZbFmlgAIQjiIWtVGSGtsI4HQrPV-r7Udlz1ag36I0B2IHp54t9arcK0p46KZEJkV3twrxPB9xDTo3qVdhcBjGJPmjCtKFacio6__QTdhjD7_1R1FGBOk-UutIDtwvg35YrMT1VNZ07phfLJ7-Pl_qDwt9s7kfmldjh8kvHrs9MHin6bIQLUHTK59itg-IJToXd_pg77jvwHu9cf5
Cites_doi 10.1186/s40425-019-0540-1
10.1038/s41420-021-00527-8
10.3390/cancers15133530
10.1158/1535-7163.MCT-21-0554
10.1007/s00259-024-06714-w
10.1038/s41572-019-0125-9
10.1186/s12935-015-0195-z
10.18632/oncotarget.11950
10.1038/s41419-024-06791-7
10.1016/j.prp.2024.155267
10.3892/ol.2014.2268
10.1200/JCO.2016.34.15_suppl.TPS3104
10.1111/pcmr.13091
10.1186/s13045-022-01364-7
10.1007/s10637-017-0520-6
10.36401/JIPO-23-18
10.1016/j.canlet.2024.216713
10.1158/0008-5472.CAN-23-4099
10.3390/biom12121744
10.1002/ijc.26238
10.1038/s41374-019-0238-5
10.1021/acsnano.2c02850
10.7150/jca.17759
10.1007/s12105-020-01222-3
10.1136/jitc-2023-007174
10.1136/jitc-2023-008662
10.7861/clinmedicine.17-3-220
10.3892/mmr.2012.1158
10.1172/JCI162148
10.7150/jca.51604
10.1111/cas.13744
10.1080/15384047.2022.2123675
10.1186/s40478-021-01167-w
10.1042/BSR20201054
10.1007/s12094-024-03792-y
10.1016/j.bbrc.2019.04.142
10.1080/2162402X.2020.1748991
10.1007/s10517-023-05972-2
10.1158/1078-0432.CCR-20-4221
10.3389/fimmu.2022.817296
10.1007/s00262-021-02862-2
10.1002/cncr.34190
10.1002/iid3.70005
10.1080/15384101.2022.2105087
10.1038/ni967
10.1101/2024.05.23.595624
10.2174/0929867326666190228120908
10.3389/fimmu.2024.1344272
10.1136/jitc-2021-004424
10.3892/ijo.2011.949
10.1080/08830185.2022.2102619
10.1158/1535-7163.MCT-11-0072
10.1016/j.molimm.2019.10.026
10.1007/s12010-023-04606-7
10.1111/jcmm.18575
10.1002/eji.200839028
10.1080/2162402X.2024.2419686
10.3892/or.2016.4607
10.1186/s12885-024-13238-x
10.1038/s41523-024-00618-6
10.1038/s41467-023-36881-7
10.1016/j.immuni.2022.03.008
10.3389/fimmu.2021.757047
10.2147/IJGM.S395553
10.1111/1759-7714.15193
10.3389/fimmu.2021.701006
10.21037/tcr-19-2910
10.3390/cells14070530
10.3389/fonc.2024.1408051
10.1016/j.anndiagpath.2020.151483
10.1016/j.biologicals.2022.08.006
10.1016/j.it.2022.04.010
10.1007/s00432-022-04244-2
10.1038/s41388-018-0407-9
10.1016/j.prp.2020.153219
10.3389/fonc.2023.1192448
10.2147/OTT.S147041
10.1016/j.lfs.2021.119438
10.1182/blood.2019001641
10.1016/j.immuni.2021.04.004
10.1186/s13045-022-01383-4
10.1016/j.asjsur.2023.07.080
10.1172/JCI155621
10.1016/j.omto.2020.03.019
10.1016/j.ygyno.2021.04.013
10.1016/j.ccr.2009.06.018
10.1200/JCO.23.00013
10.1158/2326-6066.CIR-21-0407
10.1097/PGP.0000000000000116
10.1007/s00262-020-02771-w
10.3390/ijms25073976
10.1002/2211-5463.13280
10.3892/or.2023.8556
10.1016/j.ejca.2020.03.033
10.1038/s41467-024-51096-0
10.1158/1078-0432.CCR-16-3107
10.1097/PAI.0000000000001001
10.7150/ijbs.87763
10.1155/2020/1283632
10.1186/s12894-024-01446-3
10.1038/s41591-024-03451-3
10.3748/wjg.v21.i6.1804
10.1016/j.molimm.2023.12.002
10.1111/jcmm.18360
10.1007/s11060-012-1021-2
10.1038/s41419-022-04542-0
10.1073/pnas.0802423105
10.1016/j.lungcan.2009.01.017
10.1038/nri2154
10.1158/1078-0432.CCR-18-0432
10.1016/j.bcp.2020.114298
10.1038/s41467-022-29647-0
10.1038/s41591-023-02284-w
10.1093/neuonc/noad205
10.1080/19420862.2016.1156829
10.1016/j.annonc.2021.08.1133
10.1007/s12094-021-02762-y
10.1158/1535-7163.MCT-20-0116
10.1016/j.wneu.2019.10.044
10.1126/scitranslmed.adf6724
10.1002/advs.202205532
10.1038/s41591-020-0821-8
10.1186/s12916-016-0623-5
10.1002/bco2.418
10.3390/ijms221910719
10.1038/s41598-021-94360-9
10.3389/fimmu.2022.888713
10.3390/cancers16112140
10.1016/j.intimp.2024.113004
10.1038/jid.2013.114
10.1126/scitranslmed.adf6732
10.1186/s12943-023-01751-9
10.1136/jitc-2024-009544
10.1016/j.trecan.2018.03.010
10.1038/s41417-023-00644-9
10.21037/jtd.2020.04.41
10.3389/fimmu.2021.744823
10.1016/j.lungcan.2006.05.012
10.1016/j.immuni.2016.05.002
10.1111/jcmm.13143
10.1016/j.tranon.2023.101874
10.3389/fimmu.2022.818411
10.1002/advs.202415577
10.1007/s00262-021-02856-0
10.1038/85339
10.3390/ijms21197050
10.1016/j.molimm.2024.10.006
10.1016/j.bbcan.2021.188636
10.1158/0008-5472.CAN-07-1068
10.1016/j.yexcr.2018.08.014
10.1158/1535-7163.MCT-24-0327
10.1016/j.trecan.2021.06.007
10.1158/1078-0432.CCR-24-0071
10.1200/JCO.20.01974
10.1016/j.ejmech.2023.115489
10.7150/ijbs.85813
10.1158/1078-0432.CCR-19-1655
10.1182/blood-2017-06-793141
10.3389/fimmu.2023.1062856
10.1136/jitc-2024-009221
10.3389/fimmu.2020.00681
10.3390/vaccines12010054
10.1126/sciadv.aax3160
10.1080/14712598.2021.1862791
10.1158/1078-0432.CCR-12-0715
10.1056/NEJMoa1200694
10.7150/thno.105947
10.3390/cancers15123136
10.1111/imm.12941
10.3892/or.2017.5858
10.1016/j.ymthe.2022.08.021
10.18632/oncotarget.13177
10.1200/JCO.19.01410
10.1016/j.tranon.2023.101801
10.1158/1078-0432.CCR-20-2540
10.3390/ijms25137334
10.1016/j.ccell.2018.01.011
10.1038/s42003-023-05736-8
10.1177/1010428318815032
10.1016/j.jtho.2022.10.002
10.4049/jimmunol.168.12.6294
10.3892/mmr.2022.12595
10.1038/s41423-019-0305-2
10.1038/nrendo.2013.125
10.1136/jitc-2024-009710
10.1016/j.eururo.2022.09.004
10.1007/s00262-024-03685-7
10.1038/s41467-021-22618-x
10.1093/neuonc/noaa295
10.1111/pcmr.12599
10.1016/j.intimp.2016.03.013
10.2147/CMAR.S209205
10.1136/jitc-2024-009110
10.1016/j.stem.2021.04.011
10.18632/oncotarget.17847
10.1158/2767-9764.CRC-23-0546
10.1016/j.prp.2021.153461
10.1371/journal.pone.0243379
10.1136/jitc-2019-000406
10.1093/neuonc/noaa278
10.1016/j.immuni.2024.01.013
10.1007/s10549-022-06520-8
10.1080/2162402X.2018.1461304
10.3892/mmr.2015.4050
10.1016/j.nucmedbio.2017.01.003
10.1111/j.1365-2567.2009.03236.x
10.1186/s13000-023-01320-0
10.1158/2159-8290.CD-22-0750
10.1038/cr.2017.90
10.1111/j.1365-2559.2008.03070.x
10.2147/OTT.S237841
10.1016/j.bbrep.2021.101089
10.3389/fonc.2021.600238
ContentType Journal Article
Copyright COPYRIGHT 2025 MDPI AG
2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2025 by the authors. 2025
Copyright_xml – notice: COPYRIGHT 2025 MDPI AG
– notice: 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2025 by the authors. 2025
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
8FD
8FE
8FH
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
GNUQQ
HCIFZ
LK8
M7P
P64
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
RC3
7X8
5PM
DOA
DOI 10.3390/cells14151209
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
Engineering Research Database
ProQuest Central Student
SciTech Premium Collection
Biological Sciences
Biological Science Database (ProQuest)
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central
ProQuest One Applied & Life Sciences
Genetics Abstracts
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
Biotechnology and BioEngineering Abstracts
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database


CrossRef
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2073-4409
ExternalDocumentID oai_doaj_org_article_db49de52d0aa4003a4595c48dcd68a01
PMC12346708
A851562371
40801642
10_3390_cells14151209
Genre Journal Article
Review
GeographicLocations New Brunswick
GeographicLocations_xml – name: New Brunswick
GroupedDBID 53G
5VS
8FE
8FH
AADQD
AAFWJ
AAYXX
ABDBF
ACUHS
ADBBV
AFKRA
AFPKN
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
CCPQU
CITATION
DIK
EBD
ESX
GROUPED_DOAJ
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M7P
MODMG
M~E
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQGLB
PROAC
RPM
CGR
CUY
CVF
ECM
EIF
NPM
PUEGO
8FD
ABUWG
AZQEC
DWQXO
FR3
GNUQQ
M48
P64
PKEHL
PQEST
PQQKQ
PQUKI
RC3
7X8
5PM
ID FETCH-LOGICAL-c4229-289e2ea83049f7efc9a9934c5901ead969641cd5a9a989a088b4402b51fcf1e93
IEDL.DBID BENPR
ISSN 2073-4409
IngestDate Wed Aug 27 01:22:16 EDT 2025
Thu Aug 21 18:26:20 EDT 2025
Tue Aug 26 09:01:29 EDT 2025
Thu Aug 14 17:21:41 EDT 2025
Wed Aug 20 23:57:30 EDT 2025
Tue Aug 19 03:41:08 EDT 2025
Thu Aug 28 04:50:41 EDT 2025
Wed Aug 13 23:57:27 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 15
Keywords B7-H3 (CD276)
solid tumors
immune checkpoint
B7-H3 clinical trials
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4229-289e2ea83049f7efc9a9934c5901ead969641cd5a9a989a088b4402b51fcf1e93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Literature Review-2
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0002-0410-8604
OpenAccessLink https://www.proquest.com/docview/3239022406?pq-origsite=%requestingapplication%
PMID 40801642
PQID 3239022406
PQPubID 2032536
ParticipantIDs doaj_primary_oai_doaj_org_article_db49de52d0aa4003a4595c48dcd68a01
pubmedcentral_primary_oai_pubmedcentral_nih_gov_12346708
proquest_miscellaneous_3239119314
proquest_journals_3239022406
gale_infotracmisc_A851562371
gale_infotracacademiconefile_A851562371
pubmed_primary_40801642
crossref_primary_10_3390_cells14151209
PublicationCentury 2000
PublicationDate 20250806
PublicationDateYYYYMMDD 2025-08-06
PublicationDate_xml – month: 8
  year: 2025
  text: 20250806
  day: 6
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Cells (Basel, Switzerland)
PublicationTitleAlternate Cells
PublicationYear 2025
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Meng (ref_31) 2021; 70
ref_137
ref_139
Tekle (ref_67) 2012; 130
Zhang (ref_78) 2020; 17
Zhang (ref_42) 2024; 41
ref_99
Haydar (ref_182) 2021; 23
ref_133
ref_95
Kong (ref_2) 2024; 21
Wang (ref_76) 2013; 133
Xie (ref_69) 2021; 11
Shepard (ref_214) 2017; 17
Kobori (ref_18) 2010; 130
Scribner (ref_197) 2020; 19
Pathania (ref_45) 2024; 15
Ding (ref_53) 2023; 16
Koyama (ref_167) 2020; 216
Sakunrangsit (ref_93) 2024; 73
Madjd (ref_160) 2020; 46
Deng (ref_161) 2024; 27
ref_127
ref_129
Baral (ref_87) 2014; 8
Chen (ref_62) 2019; 514
ref_240
Vitanza (ref_183) 2025; 31
Li (ref_64) 2017; 8
Katayama (ref_177) 2011; 38
Bam (ref_135) 2020; 26
Zhou (ref_83) 2013; 111
Shenderov (ref_199) 2021; 32
Gao (ref_33) 2021; 7
ref_71
Zong (ref_149) 2020; 2020
Zhang (ref_65) 2017; 38
Lee (ref_158) 2023; 18
Shi (ref_150) 2021; 10
Feustel (ref_208) 2024; 7
Loo (ref_210) 2012; 18
Huang (ref_94) 2021; 70
Huang (ref_148) 2016; 35
Meeus (ref_192) 2024; 12
Wu (ref_120) 2016; 7
Huang (ref_141) 2021; 12
ref_147
Deol (ref_168) 2024; 5
Zhou (ref_235) 2024; 84
Gregorio (ref_85) 2008; 53
Masters (ref_207) 2018; 36
Bray (ref_1) 2024; 74
Liao (ref_70) 2022; 25
ref_144
ref_86
Zhuang (ref_221) 2016; 35
ref_146
Brignole (ref_107) 2023; 11
Zhang (ref_228) 2024; 15
Avci (ref_134) 2022; 26
Deng (ref_55) 2021; 162
Yang (ref_74) 2024; 165
Zheng (ref_97) 2023; 19
Rosenbaum (ref_119) 2018; 24
ref_218
ref_219
Brahmer (ref_216) 2012; 366
Shen (ref_88) 2024; 28
Li (ref_159) 2024; 176
Lake (ref_226) 2024; 12
Lu (ref_230) 2020; 70
ref_211
Hegde (ref_47) 2021; 54
Burke (ref_5) 2024; 57
Zhang (ref_60) 2018; 7
Dong (ref_179) 2024; 12
Kang (ref_68) 2015; 15
Lee (ref_44) 2021; 277
ref_203
Mei (ref_140) 2024; 10
Liao (ref_176) 2021; 12
ref_202
Lu (ref_217) 2020; 9
ref_204
Yim (ref_16) 2020; 133
Xu (ref_170) 2018; 40
Mendes (ref_37) 2022; 128
Brustmann (ref_51) 2015; 34
Huang (ref_79) 2023; 10
Wang (ref_89) 2018; 109
ref_201
ref_200
Roth (ref_152) 2007; 67
Gao (ref_41) 2020; 117
Altan (ref_121) 2017; 23
Liu (ref_56) 2013; 28
Liu (ref_123) 2019; 12
Guo (ref_153) 2023; 83
Liu (ref_142) 2011; 10
Tian (ref_103) 2022; 132
Wang (ref_143) 2022; 193
Zhong (ref_66) 2020; 13
ref_238
Xiong (ref_46) 2024; 12
ref_118
Modak (ref_223) 2020; 38
Shao (ref_49) 2021; 7
ref_111
ref_110
Borgmann (ref_173) 2023; 149
ref_231
Ma (ref_30) 2024; 12
Lichtman (ref_181) 2021; 27
Lupu (ref_19) 2007; 18
Kasten (ref_222) 2020; 27
Wang (ref_92) 2023; 31
Liu (ref_63) 2019; 38
Mischinger (ref_164) 2019; 72
Tekle (ref_77) 2017; 30
Inamura (ref_15) 2019; 11
ref_105
Kendsersky (ref_106) 2021; 27
Mews (ref_112) 2022; 16
Miller (ref_25) 2024; 4
Hsu (ref_237) 2023; 36
ref_220
Shishido (ref_113) 2023; 49
Wirsing (ref_175) 2021; 15
Zhao (ref_132) 2022; 15
Zheng (ref_165) 2024; 142
Michelakos (ref_215) 2021; 21
Zhang (ref_91) 2019; 99
Kasten (ref_224) 2017; 47
Suh (ref_28) 2003; 4
Su (ref_136) 2023; 46
ref_14
ref_13
Zhu (ref_73) 2024; 196
Yamada (ref_227) 2023; 15
Chapoval (ref_8) 2001; 2
Schildberg (ref_4) 2016; 44
Sun (ref_9) 2002; 168
Cattaneo (ref_27) 2024; 587
Wang (ref_126) 2023; 18
Sun (ref_239) 2006; 53
Goldstein (ref_109) 1997; 8
Zhou (ref_232) 2025; 12
Getu (ref_7) 2023; 22
Li (ref_12) 2017; 8
ref_24
Zhang (ref_162) 2017; 10
Wang (ref_21) 2021; 28
Digregorio (ref_90) 2021; 9
Ahrends (ref_36) 2018; 154
Zhou (ref_35) 2016; 7
Peuker (ref_32) 2022; 55
Liu (ref_26) 2023; 14
Leitner (ref_20) 2009; 39
Meng (ref_72) 2023; 15
Xu (ref_58) 2018; 15
Agarwal (ref_225) 2023; 133
Cai (ref_29) 2020; 17
Deng (ref_82) 2020; 135
Park (ref_101) 2020; 38
(ref_115) 2013; 9
Zhang (ref_122) 2009; 66
DeNardo (ref_34) 2009; 16
Kim (ref_145) 2022; 30
Donaghy (ref_206) 2016; 8
Altan (ref_128) 2019; 7
Merchant (ref_114) 2019; 5
Shen (ref_75) 2024; 256
Fabrizio (ref_130) 2023; 39
Xiang (ref_104) 2024; 28
Narvekar (ref_209) 2022; 79
Zhang (ref_241) 2015; 21
Rizvi (ref_81) 2016; 34
Kramer (ref_108) 2022; 15
Tian (ref_157) 2024; 51
Majzner (ref_102) 2019; 25
Li (ref_156) 2022; 23
ref_50
Emaldi (ref_57) 2024; 13
Shi (ref_155) 2023; 15
Li (ref_125) 2020; 12
ref_172
ref_174
ref_54
ref_52
ref_180
Moore (ref_233) 2025; 24
Hashiguchi (ref_17) 2008; 105
Zhang (ref_23) 2022; 43
Shenderov (ref_213) 2023; 29
Kovaleva (ref_10) 2023; 176
ref_169
Lee (ref_59) 2017; 27
Wang (ref_117) 2020; 8
Li (ref_178) 2022; 13
ref_163
ref_166
Li (ref_184) 2022; 13
Liu (ref_131) 2013; 7
Passaro (ref_205) 2023; 41
Miyamoto (ref_22) 2022; 10
Wang (ref_236) 2025; 13
ref_171
Mao (ref_96) 2023; 257
Aggarwal (ref_212) 2022; 10
You (ref_234) 2021; 7
Huntington (ref_43) 2007; 7
Shao (ref_138) 2021; 224
Costa (ref_38) 2018; 33
Han (ref_151) 2018; 371
Ma (ref_229) 2025; 15
ref_196
ref_198
Mao (ref_39) 2017; 21
Li (ref_193) 2022; 41
Kang (ref_154) 2023; 30
Nie (ref_124) 2022; 21
Hay (ref_194) 2017; 130
Patil (ref_98) 2021; 23
Ventin (ref_80) 2024; 30
Theruvath (ref_84) 2020; 26
Curran (ref_195) 2019; 134
ref_186
ref_185
ref_188
Coy (ref_116) 2023; 26
ref_187
ref_40
ref_189
ref_3
Li (ref_61) 2022; 24
ref_191
ref_190
ref_48
Fodstad (ref_11) 2018; 4
Vitanza (ref_100) 2023; 13
ref_6
Liu (ref_242) 2015; 12
References_xml – volume: 7
  start-page: 65
  year: 2019
  ident: ref_128
  article-title: Expression and Clinical Significance of PD-L1, B7-H3, B7-H4 and TILs in Human Small Cell Lung Cancer (SCLC)
  publication-title: J. Immunother. Cancer
  doi: 10.1186/s40425-019-0540-1
– ident: ref_190
– volume: 7
  start-page: 145
  year: 2021
  ident: ref_49
  article-title: MicroRNA-326 Attenuates Immune Escape and Prevents Metastasis in Lung Adenocarcinoma by Targeting PD-L1 and B7-H3
  publication-title: Cell Death Discov.
  doi: 10.1038/s41420-021-00527-8
– ident: ref_231
  doi: 10.3390/cancers15133530
– ident: ref_198
  doi: 10.1158/1535-7163.MCT-21-0554
– volume: 51
  start-page: 2569
  year: 2024
  ident: ref_157
  article-title: Enhancing Surgical Outcomes: Accurate Identification and Removal of Prostate Cancer with B7-H3-Targeted NIR-II Molecular Imaging
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-024-06714-w
– volume: 5
  start-page: 75
  year: 2019
  ident: ref_114
  article-title: Craniopharyngioma
  publication-title: Nat. Rev. Dis. Primers
  doi: 10.1038/s41572-019-0125-9
– volume: 15
  start-page: 45
  year: 2015
  ident: ref_68
  article-title: B7-H3 Promotes Aggression and Invasion of Hepatocellular Carcinoma by Targeting Epithelial-to-Mesenchymal Transition via JAK2/STAT3/Slug Signaling Pathway
  publication-title: Cancer Cell Int.
  doi: 10.1186/s12935-015-0195-z
– volume: 7
  start-page: 67196
  year: 2016
  ident: ref_35
  article-title: TGF-Β1 Promotes Colorectal Cancer Immune Escape by Elevating B7-H3 and B7-H4 via the miR-155/miR-143 Axis
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.11950
– volume: 15
  start-page: 428
  year: 2024
  ident: ref_45
  article-title: The miR-29 Family Facilitates the Activation of NK-Cell Immune Responses by Targeting the B7-H3 Immune Checkpoint in Neuroblastoma
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-024-06791-7
– volume: 74
  start-page: 229
  year: 2024
  ident: ref_1
  article-title: Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
  publication-title: CA A Cancer J. Clin.
– volume: 256
  start-page: 155267
  year: 2024
  ident: ref_75
  article-title: B7-H3 Is Associated with the Armored-Cold Phenotype and Predicts Poor Immune Checkpoint Blockade Response in Melanoma
  publication-title: Pathol.-Res. Pract.
  doi: 10.1016/j.prp.2024.155267
– volume: 8
  start-page: 1195
  year: 2014
  ident: ref_87
  article-title: B7-H3 and B7-H1 Expression in Cerebral Spinal Fluid and Tumor Tissue Correlates with the Malignancy Grade of Glioma Patients
  publication-title: Oncol. Lett.
  doi: 10.3892/ol.2014.2268
– volume: 34
  start-page: TPS3104
  year: 2016
  ident: ref_81
  article-title: A Phase 1 Study of Enoblituzumab in Combination with Pembrolizumab in Patients with Advanced B7-H3-Expressing Cancers
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2016.34.15_suppl.TPS3104
– volume: 36
  start-page: 407
  year: 2023
  ident: ref_237
  article-title: B7-H3 Drives Immunosuppression and Co-targeting with CD47 Is a New Therapeutic Strategy in Β-catenin Activated Melanomas
  publication-title: Pigment Cell Melanoma Res.
  doi: 10.1111/pcmr.13091
– volume: 15
  start-page: 153
  year: 2022
  ident: ref_132
  article-title: Immune Checkpoint of B7-H3 in Cancer: From Immunology to Clinical Immunotherapy
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-022-01364-7
– volume: 36
  start-page: 121
  year: 2018
  ident: ref_207
  article-title: Clinical Toxicity of Antibody Drug Conjugates: A Meta-Analysis of Payloads
  publication-title: Investig. New Drugs
  doi: 10.1007/s10637-017-0520-6
– volume: 7
  start-page: 53
  year: 2024
  ident: ref_208
  article-title: B7-H3 Inhibitors in Oncology Clinical Trials: A Review
  publication-title: J. Immunother. Precis. Oncol.
  doi: 10.36401/JIPO-23-18
– volume: 587
  start-page: 216713
  year: 2024
  ident: ref_27
  article-title: Interplay between B7-H3 and HLA Class I in the Clinical Course of Pancreatic Ductal Adenocarcinoma
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2024.216713
– volume: 84
  start-page: 3848
  year: 2024
  ident: ref_235
  article-title: A Dual-Payload Antibody–Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-23-4099
– ident: ref_118
  doi: 10.3390/biom12121744
– volume: 130
  start-page: 2282
  year: 2012
  ident: ref_67
  article-title: B7-H3 Contributes to the Metastatic Capacity of Melanoma Cells by Modulation of Known Metastasis-Associated Genes
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.26238
– volume: 99
  start-page: 1117
  year: 2019
  ident: ref_91
  article-title: B7H3 Regulates Differentiation and Serves as a Potential Biomarker and Theranostic Target for Human Glioblastoma
  publication-title: Lab. Investig.
  doi: 10.1038/s41374-019-0238-5
– volume: 16
  start-page: 12185
  year: 2022
  ident: ref_112
  article-title: Multivalent, Bispecific αB7-H3-αCD3 Chemically Self-Assembled Nanorings Direct Potent T Cell Responses Against Medulloblastoma
  publication-title: ACS Nano
  doi: 10.1021/acsnano.2c02850
– volume: 8
  start-page: 816
  year: 2017
  ident: ref_12
  article-title: B7-H3 Promotes the Migration and Invasion of Human Bladder Cancer Cells via the PI3K/Akt/STAT3 Signaling Pathway
  publication-title: J. Cancer
  doi: 10.7150/jca.17759
– volume: 15
  start-page: 469
  year: 2021
  ident: ref_175
  article-title: Evaluation Challenges in the Validation of B7-H3 as Oral Tongue Cancer Prognosticator
  publication-title: Head. Neck Pathol.
  doi: 10.1007/s12105-020-01222-3
– volume: 11
  start-page: e007174
  year: 2023
  ident: ref_107
  article-title: Antitumor Activity of the Investigational B7-H3 Antibody-Drug Conjugate, Vobramitamab Duocarmazine, in Preclinical Models of Neuroblastoma
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2023-007174
– volume: 12
  start-page: e008662
  year: 2024
  ident: ref_46
  article-title: CD276 Regulates the Immune Escape of Esophageal Squamous Cell Carcinoma through CXCL1–CXCR2 Induced NETs
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2023-008662
– volume: 17
  start-page: 220
  year: 2017
  ident: ref_214
  article-title: Developments in Therapy with Monoclonal Antibodies and Related Proteins
  publication-title: Clin. Med.
  doi: 10.7861/clinmedicine.17-3-220
– volume: 7
  start-page: 134
  year: 2013
  ident: ref_131
  article-title: B7-H3 Expression in Ductal and Lobular Breast Cancer and Its Association with IL-10
  publication-title: Mol. Med. Rep.
  doi: 10.3892/mmr.2012.1158
– volume: 40
  start-page: 2722
  year: 2018
  ident: ref_170
  article-title: B7-H3 Promotes Malignant Progression of Muscle-invasive Bladder Cancer
  publication-title: Oncol. Rep.
– volume: 133
  start-page: e162148
  year: 2023
  ident: ref_225
  article-title: Tumor-Derived Biomarkers Predict Efficacy of B7H3 Antibody-Drug Conjugate Treatment in Metastatic Prostate Cancer Models
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI162148
– volume: 12
  start-page: 1455
  year: 2021
  ident: ref_176
  article-title: Changes in Protein Glycosylation in Head and Neck Squamous Cell Carcinoma
  publication-title: J. Cancer
  doi: 10.7150/jca.51604
– volume: 109
  start-page: 2697
  year: 2018
  ident: ref_89
  article-title: Genetic and Clinical Characterization of B7-H3 (CD276) Expression and Epigenetic Regulation in Diffuse Brain Glioma
  publication-title: Cancer Sci.
  doi: 10.1111/cas.13744
– volume: 12
  start-page: 3032
  year: 2019
  ident: ref_123
  article-title: The Expressions and Significance of B7-H3 and CTLA-4 in the Clinical Stages of Non-Small-Cell Lung Cancer
  publication-title: Int. J. Clin. Exp. Pathol.
– volume: 23
  start-page: 1
  year: 2022
  ident: ref_156
  article-title: Suppressive Function of Bone Marrow-Derived Mesenchymal Stem Cell-Derived Exosomal microRNA-187 in Prostate Cancer
  publication-title: Cancer Biol. Ther.
  doi: 10.1080/15384047.2022.2123675
– volume: 9
  start-page: 59
  year: 2021
  ident: ref_90
  article-title: The Expression of B7-H3 Isoforms in Newly Diagnosed Glioblastoma and Recurrence and Their Functional Role
  publication-title: Acta Neuropathol. Commun.
  doi: 10.1186/s40478-021-01167-w
– ident: ref_144
  doi: 10.1042/BSR20201054
– volume: 27
  start-page: 2667
  year: 2024
  ident: ref_161
  article-title: Development of B7-H3 Targeted CAR-T Cells for Renal Cell Carcinoma Therapy: In Vitro and in Vivo Efficacy
  publication-title: Clin. Transl. Oncol.
  doi: 10.1007/s12094-024-03792-y
– volume: 514
  start-page: 379
  year: 2019
  ident: ref_62
  article-title: Frequent B7-H3 Overexpression in Craniopharyngioma
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2019.04.142
– volume: 9
  start-page: 1748991
  year: 2020
  ident: ref_217
  article-title: B7-H3 Inhibits the IFN-γ-Dependent Cytotoxicity of Vγ9Vδ2 T Cells against Colon Cancer Cells
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2020.1748991
– volume: 176
  start-page: 87
  year: 2023
  ident: ref_10
  article-title: Soluble B7-H3 in Colorectal Cancer
  publication-title: Bull. Exp. Biol. Med.
  doi: 10.1007/s10517-023-05972-2
– volume: 27
  start-page: 2938
  year: 2021
  ident: ref_106
  article-title: The B7-H3-Targeting Antibody-Drug Conjugate M276-SL-PBD Is Potently Effective against Pediatric Cancer Preclinical Solid Tumor Models
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-20-4221
– ident: ref_95
  doi: 10.3389/fimmu.2022.817296
– volume: 70
  start-page: 2247
  year: 2021
  ident: ref_31
  article-title: miR-34a Induces Immunosuppression in Colorectal Carcinoma through Modulating a SIRT1/NF-κB/B7-H3/TNF-α Axis
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-021-02862-2
– volume: 128
  start-page: 2269
  year: 2022
  ident: ref_37
  article-title: Association of B7-H3 Expression with Racial Ancestry, Immune Cell Density, and Androgen Receptor Activation in Prostate Cancer
  publication-title: Cancer
  doi: 10.1002/cncr.34190
– volume: 12
  start-page: e70005
  year: 2024
  ident: ref_30
  article-title: B7-H3 Promotes Nasopharyngeal Carcinoma Progression by Regulating CD8+ T Cell Exhaustion
  publication-title: Immun. Inflamm. Dis.
  doi: 10.1002/iid3.70005
– volume: 21
  start-page: 2575
  year: 2022
  ident: ref_124
  article-title: Circular RNA circFARSA Promotes the Tumorigenesis of Non-Small Cell Lung Cancer by Elevating B7H3 via Sponging miR-15a-5p
  publication-title: Cell Cycle
  doi: 10.1080/15384101.2022.2105087
– volume: 4
  start-page: 899
  year: 2003
  ident: ref_28
  article-title: The B7 Family Member B7-H3 Preferentially down-Regulates T Helper Type 1-Mediated Immune Responses
  publication-title: Nat. Immunol.
  doi: 10.1038/ni967
– ident: ref_105
  doi: 10.1101/2024.05.23.595624
– volume: 27
  start-page: 4016
  year: 2020
  ident: ref_222
  article-title: B7-H3-Targeted Radioimmunotherapy of Human Cancer
  publication-title: Curr. Med. Chem.
  doi: 10.2174/0929867326666190228120908
– ident: ref_24
  doi: 10.3389/fimmu.2024.1344272
– ident: ref_191
– ident: ref_200
– volume: 10
  start-page: e004424
  year: 2022
  ident: ref_212
  article-title: Dual Checkpoint Targeting of B7-H3 and PD-1 with Enoblituzumab and Pembrolizumab in Advanced Solid Tumors: Interim Results from a Multicenter Phase I/II Trial
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2021-004424
– volume: 38
  start-page: 1219
  year: 2011
  ident: ref_177
  article-title: Expression of B7-H3 in Hypopharyngeal Squamous Cell Carcinoma as a Predictive Indicator for Tumor Metastasis and Prognosis
  publication-title: Int. J. Oncol.
  doi: 10.3892/ijo.2011.949
– volume: 41
  start-page: 625
  year: 2022
  ident: ref_193
  article-title: B7-H3-Targeted CAR-T Cell Therapy for Solid Tumors
  publication-title: Int. Rev. Immunol.
  doi: 10.1080/08830185.2022.2102619
– volume: 18
  start-page: 745
  year: 2007
  ident: ref_19
  article-title: Adenoviral B7-H3 Therapy Induces Tumor Specific Immune Responses and Reduces Secondary Metastasis in a Murine Model of Colon Cancer
  publication-title: Oncol. Rep.
– volume: 10
  start-page: 960
  year: 2011
  ident: ref_142
  article-title: B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-11-0072
– volume: 117
  start-page: 20
  year: 2020
  ident: ref_41
  article-title: LncRNA NEAT1 Sponges miR-214 to Regulate M2 Macrophage Polarization by Regulation of B7-H3 in Multiple Myeloma
  publication-title: Mol. Immunol.
  doi: 10.1016/j.molimm.2019.10.026
– volume: 196
  start-page: 1386
  year: 2024
  ident: ref_73
  article-title: B7-H3 Regulates Glucose Metabolism in Neuroblastom via Stat3/c-Met Pathway
  publication-title: Appl. Biochem. Biotechnol.
  doi: 10.1007/s12010-023-04606-7
– volume: 28
  start-page: e18575
  year: 2024
  ident: ref_88
  article-title: Generation of B7-H3 Isoform Regulated by ANXA2/NSUN2/YBX1 Axis in Human Glioma
  publication-title: J. Cell. Mol. Med.
  doi: 10.1111/jcmm.18575
– volume: 39
  start-page: 1754
  year: 2009
  ident: ref_20
  article-title: B7-H3 Is a Potent Inhibitor of Human T-Cell Activation: No Evidence for B7-H3 and TREML2 Interaction
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.200839028
– ident: ref_185
– volume: 13
  start-page: 2419686
  year: 2024
  ident: ref_57
  article-title: Impact of B7-H3 Expression on Metastasis, Immune Exhaustion and JAK/STAT and PI3K/AKT Pathways in Clear Cell Renal Cell Carcinoma
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2024.2419686
– volume: 35
  start-page: 2183
  year: 2016
  ident: ref_148
  article-title: B7-H3, B7-H4, Foxp3 and IL-2 Expression in Cervical Cancer: Associations with Patient Outcome and Clinical Significance
  publication-title: Oncol. Rep.
  doi: 10.3892/or.2016.4607
– ident: ref_163
  doi: 10.1186/s12885-024-13238-x
– volume: 10
  start-page: 11
  year: 2024
  ident: ref_140
  article-title: High B7-H3 Expression with Low PD-L1 Expression Identifies Armored-Cold Tumors in Triple-Negative Breast Cancer
  publication-title: NPJ Breast Cancer
  doi: 10.1038/s41523-024-00618-6
– volume: 14
  start-page: 1214
  year: 2023
  ident: ref_26
  article-title: mTORC1 Upregulates B7-H3/CD276 to Inhibit Antitumor T Cells and Drive Tumor Immune Evasion
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-023-36881-7
– volume: 55
  start-page: 701
  year: 2022
  ident: ref_32
  article-title: Microbiota-Dependent Activation of the Myeloid Calcineurin-NFAT Pathway Inhibits B7H3- and B7H4-Dependent Anti-Tumor Immunity in Colorectal Cancer
  publication-title: Immunity
  doi: 10.1016/j.immuni.2022.03.008
– ident: ref_172
  doi: 10.3389/fimmu.2021.757047
– volume: 16
  start-page: 367
  year: 2023
  ident: ref_53
  article-title: Comprehensive Analysis Reveals Distinct Immunological and Prognostic Characteristics of CD276/B7-H3 in Pan-Cancer
  publication-title: Int. J. Gen. Med.
  doi: 10.2147/IJGM.S395553
– volume: 15
  start-page: 316
  year: 2023
  ident: ref_72
  article-title: Disruption of LPA-LPAR1 Pathway Results in Lung Tumor Growth Inhibition by Downregulating B7-H3 Expression in Fibroblasts
  publication-title: Thorac. Cancer
  doi: 10.1111/1759-7714.15193
– ident: ref_196
  doi: 10.3389/fimmu.2021.701006
– volume: 15
  start-page: 6519
  year: 2018
  ident: ref_58
  article-title: High Expression of B7-H3 and CD163 in Cancer Tissues Indicates Malignant Clinicopathological Status and Poor Prognosis of Patients with Urothelial Cell Carcinoma of the Bladder
  publication-title: Oncol. Lett.
– volume: 10
  start-page: 65
  year: 2021
  ident: ref_150
  article-title: CD276 (B7H3) Improve Cancer Stem Cells Formation in Cervical Carcinoma Cell Lines
  publication-title: Transl. Cancer Res.
  doi: 10.21037/tcr-19-2910
– ident: ref_14
  doi: 10.3390/cells14070530
– ident: ref_13
  doi: 10.3389/fonc.2024.1408051
– ident: ref_188
– volume: 46
  start-page: 151483
  year: 2020
  ident: ref_160
  article-title: Cytoplasmic Expression of B7-H3 and Membranous EpCAM Expression Are Associated with Higher Grade and Survival Outcomes in Patients with Clear Cell Renal Cell Carcinoma
  publication-title: Ann. Diagn. Pathol.
  doi: 10.1016/j.anndiagpath.2020.151483
– volume: 79
  start-page: 10
  year: 2022
  ident: ref_209
  article-title: ADCC Enhancement: A Conundrum or a Boon to mAb Therapy?
  publication-title: Biologicals
  doi: 10.1016/j.biologicals.2022.08.006
– volume: 43
  start-page: 523
  year: 2022
  ident: ref_23
  article-title: Turning Cold Tumors Hot: From Molecular Mechanisms to Clinical Applications
  publication-title: Trends Immunol.
  doi: 10.1016/j.it.2022.04.010
– volume: 149
  start-page: 3383
  year: 2023
  ident: ref_173
  article-title: The Prognostic Impact of B7-H3 and B7-H4 in Head and Neck Squamous Cell Carcinoma
  publication-title: J. Cancer Res. Clin. Oncol.
  doi: 10.1007/s00432-022-04244-2
– volume: 38
  start-page: 88
  year: 2019
  ident: ref_63
  article-title: Immunoregulatory Protein B7-H3 Regulates Cancer Stem Cell Enrichment and Drug Resistance through MVP-Mediated MEK Activation
  publication-title: Oncogene
  doi: 10.1038/s41388-018-0407-9
– volume: 216
  start-page: 153219
  year: 2020
  ident: ref_167
  article-title: B7-H3 Expression in Upper Tract Urothelial Carcinoma Associates with Adverse Clinicopathological Features and Poor Survival
  publication-title: Pathol.-Res. Pract.
  doi: 10.1016/j.prp.2020.153219
– ident: ref_99
  doi: 10.3389/fonc.2023.1192448
– volume: 10
  start-page: 5417
  year: 2017
  ident: ref_162
  article-title: Expression and Significance of B7-H3 and Tie-2 in the Tumor Vasculature of Clear Cell Renal Carcinoma
  publication-title: Onco Targets Ther.
  doi: 10.2147/OTT.S147041
– volume: 277
  start-page: 119438
  year: 2021
  ident: ref_44
  article-title: A Regulatory Loop among CD276, miR-29c-3p, and Myc Exists in Cancer Cells against Natural Killer Cell Cytotoxicity
  publication-title: Life Sci.
  doi: 10.1016/j.lfs.2021.119438
– volume: 134
  start-page: 2361
  year: 2019
  ident: ref_195
  article-title: Toxicity and Response after CD19-Specific CAR T-Cell Therapy in Pediatric/Young Adult Relapsed/Refractory B-ALL
  publication-title: Blood
  doi: 10.1182/blood.2019001641
– volume: 54
  start-page: 875
  year: 2021
  ident: ref_47
  article-title: MDSC: Markers, Development, States, and Unaddressed Complexity
  publication-title: Immunity
  doi: 10.1016/j.immuni.2021.04.004
– volume: 15
  start-page: 165
  year: 2022
  ident: ref_108
  article-title: Phase 1 Study of Intraventricular 131I-Omburtamab Targeting B7H3 (CD276)-Expressing CNS Malignancies
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-022-01383-4
– volume: 46
  start-page: 5323
  year: 2023
  ident: ref_136
  article-title: Clinicopathological Features and Prognostic Value of CD276 Expression in Breast Cancer: A Meta-Analysis
  publication-title: Asian J. Surg.
  doi: 10.1016/j.asjsur.2023.07.080
– volume: 132
  start-page: e155621
  year: 2022
  ident: ref_103
  article-title: An Optimized Bicistronic Chimeric Antigen Receptor against GPC2 or CD276 Overcomes Heterogeneous Expression in Neuroblastoma
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI155621
– volume: 17
  start-page: 180
  year: 2020
  ident: ref_78
  article-title: B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors
  publication-title: Mol. Ther. Oncolytics
  doi: 10.1016/j.omto.2020.03.019
– volume: 162
  start-page: 190
  year: 2021
  ident: ref_55
  article-title: MiR-29c Downregulates Tumor-Expressed B7-H3 to Mediate the Antitumor NK-Cell Functions in Ovarian Cancer
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2021.04.013
– volume: 16
  start-page: 91
  year: 2009
  ident: ref_34
  article-title: CD4+ T Cells Regulate Pulmonary Metastasis of Mammary Carcinomas by Enhancing Protumor Properties of Macrophages
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2009.06.018
– volume: 41
  start-page: 3747
  year: 2023
  ident: ref_205
  article-title: Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.23.00013
– volume: 10
  start-page: 56
  year: 2022
  ident: ref_22
  article-title: B7-H3 Suppresses Antitumor Immunity via the CCL2–CCR2–M2 Macrophage Axis and Contributes to Ovarian Cancer Progression
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-21-0407
– volume: 34
  start-page: 187
  year: 2015
  ident: ref_51
  article-title: Epithelial and Tumor-Associated Endothelial Expression of B7-H3 in Cervical Carcinoma: Relation with CD8+ Intraepithelial Lymphocytes, FIGO Stage, and Phosphohistone H3 (PHH3) Reactivity
  publication-title: Int. J. Gynecol. Pathol.
  doi: 10.1097/PGP.0000000000000116
– volume: 70
  start-page: 1213
  year: 2020
  ident: ref_230
  article-title: B7-H3 Confers Resistance to Vγ9Vδ2 T Cell-Mediated Cytotoxicity in Human Colon Cancer Cells via the STAT3/ULBP2 Axis
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-020-02771-w
– ident: ref_137
  doi: 10.3390/ijms25073976
– volume: 11
  start-page: 2977
  year: 2021
  ident: ref_69
  article-title: Fibronectin Enhances Tumor Metastasis through B7-H3 in Clear Cell Renal Cell Carcinoma
  publication-title: FEBS Open Bio
  doi: 10.1002/2211-5463.13280
– volume: 72
  start-page: 23
  year: 2019
  ident: ref_164
  article-title: Prognostic Value of B7-H1, B7-H3 and the Stage, Size, Grade and Necrosis (SSIGN) Score in Metastatic Clear Cell Renal Cell Carcinoma
  publication-title: Cent. Eur. J. Urol.
– volume: 49
  start-page: 119
  year: 2023
  ident: ref_113
  article-title: Targeting B7-H3 through EZH2 Inhibition in MYC-positive Group 3 Medulloblastoma
  publication-title: Oncol. Rep.
  doi: 10.3892/or.2023.8556
– volume: 133
  start-page: 74
  year: 2020
  ident: ref_16
  article-title: Effects of B7-H3 Expression on Tumour-Infiltrating Immune Cells and Clinicopathological Characteristics in Non–Small-Cell Lung Cancer
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2020.03.033
– volume: 15
  start-page: 7077
  year: 2024
  ident: ref_228
  article-title: ITGB6 Modulates Resistance to Anti-CD276 Therapy in Head and Neck Cancer by Promoting PF4+ Macrophage Infiltration
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-024-51096-0
– volume: 23
  start-page: 5202
  year: 2017
  ident: ref_121
  article-title: B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor Infiltrating Lymphocytes
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-16-3107
– volume: 30
  start-page: 246
  year: 2022
  ident: ref_145
  article-title: Comparison of the Clinicopathologic Features and T-Cell Infiltration of B7-H3 and B7-H4 Expression in Triple-Negative Breast Cancer Subtypes
  publication-title: Appl. Immunohistochem. Mol. Morphol.
  doi: 10.1097/PAI.0000000000001001
– volume: 19
  start-page: 4278
  year: 2023
  ident: ref_97
  article-title: Radioimmunotherapy Targeting B7-H3 in Situ Glioma Models Enhanced Antitumor Efficacy by Reconstructing the Tumor Microenvironment
  publication-title: Int. J. Biol. Sci.
  doi: 10.7150/ijbs.87763
– volume: 2020
  start-page: 1283632
  year: 2020
  ident: ref_149
  article-title: Expression and Significance of Immune Checkpoints in Clear Cell Carcinoma of the Uterine Cervix
  publication-title: J. Immunol. Res.
  doi: 10.1155/2020/1283632
– ident: ref_166
  doi: 10.1186/s12894-024-01446-3
– volume: 31
  start-page: 861
  year: 2025
  ident: ref_183
  article-title: Intracerebroventricular B7-H3-Targeting CAR T Cells for Diffuse Intrinsic Pontine Glioma: A Phase 1 Trial
  publication-title: Nat. Med.
  doi: 10.1038/s41591-024-03451-3
– ident: ref_189
– volume: 21
  start-page: 1804
  year: 2015
  ident: ref_241
  article-title: Overexpression of B7-H3 Augments Anti-Apoptosis of Colorectal Cancer Cells by Jak2-STAT3
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.v21.i6.1804
– volume: 165
  start-page: 19
  year: 2024
  ident: ref_74
  article-title: B7-H3 Promotes Angiogenesis in Rheumatoid Arthritis
  publication-title: Mol. Immunol.
  doi: 10.1016/j.molimm.2023.12.002
– volume: 28
  start-page: e18360
  year: 2024
  ident: ref_104
  article-title: NR1D1-transactivated lncRNA NUTM2A-AS1 Promotes Chemoresistance and Immune Evasion in Neuroblastoma via Inhibiting B7-H3 Degradation
  publication-title: J. Cell Mol. Med.
  doi: 10.1111/jcmm.18360
– volume: 111
  start-page: 257
  year: 2013
  ident: ref_83
  article-title: B7-H3, a Potential Therapeutic Target, Is Expressed in Diffuse Intrinsic Pontine Glioma
  publication-title: J. Neurooncol.
  doi: 10.1007/s11060-012-1021-2
– volume: 13
  start-page: 109
  year: 2022
  ident: ref_178
  article-title: LINC01123 Promotes Immune Escape by Sponging miR-214-3p to Regulate B7–H3 in Head and Neck Squamous-Cell Carcinoma
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-022-04542-0
– volume: 105
  start-page: 10495
  year: 2008
  ident: ref_17
  article-title: Triggering Receptor Expressed on Myeloid Cell-like Transcript 2 (TLT-2) Is a Counter-Receptor for B7-H3 and Enhances T Cell Responses
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.0802423105
– volume: 66
  start-page: 245
  year: 2009
  ident: ref_122
  article-title: Diagnosis Value of Serum B7-H3 Expression in Non-Small Cell Lung Cancer
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2009.01.017
– volume: 7
  start-page: 703
  year: 2007
  ident: ref_43
  article-title: Developmental Pathways That Generate Natural-Killer-Cell Diversity in Mice and Humans
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri2154
– volume: 25
  start-page: 2560
  year: 2019
  ident: ref_102
  article-title: CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-0432
– ident: ref_139
  doi: 10.1016/j.bcp.2020.114298
– volume: 13
  start-page: 2154
  year: 2022
  ident: ref_184
  article-title: Targeting Brain Lesions of Non-Small Cell Lung Cancer by Enhancing CCL2-Mediated CAR-T Cell Migration
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-29647-0
– volume: 29
  start-page: 888
  year: 2023
  ident: ref_213
  article-title: Neoadjuvant Enoblituzumab in Localized Prostate Cancer: A Single-Arm, Phase 2 Trial
  publication-title: Nat. Med.
  doi: 10.1038/s41591-023-02284-w
– ident: ref_204
– volume: 26
  start-page: 458
  year: 2023
  ident: ref_116
  article-title: Systematic Characterization of Antibody–Drug Conjugate Targets in Central Nervous System Tumors
  publication-title: Neuro Oncol.
  doi: 10.1093/neuonc/noad205
– volume: 8
  start-page: 659
  year: 2016
  ident: ref_206
  article-title: Effects of Antibody, Drug and Linker on the Preclinical and Clinical Toxicities of Antibody-Drug Conjugates
  publication-title: mAbs
  doi: 10.1080/19420862.2016.1156829
– ident: ref_203
– volume: 26
  start-page: 27
  year: 2022
  ident: ref_134
  article-title: Soluble B7H3 Level in Breast Cancer and Its Relationship with Clinicopathological Variables and T Cell Infiltration
  publication-title: Contemp. Oncol.
– volume: 32
  start-page: S657
  year: 2021
  ident: ref_199
  article-title: 620P MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in Patients with Advanced Solid Tumors: Preliminary Results of Phase I Cohort Expansion
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2021.08.1133
– volume: 24
  start-page: 1204
  year: 2022
  ident: ref_61
  article-title: Pediatric Medulloblastoma Express Immune Checkpoint B7-H3
  publication-title: Clin. Transl. Oncol.
  doi: 10.1007/s12094-021-02762-y
– volume: 19
  start-page: 2235
  year: 2020
  ident: ref_197
  article-title: Preclinical Development of MGC018, a Duocarmycin-Based Antibody–Drug Conjugate Targeting B7-H3 for Solid Cancer
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-20-0116
– volume: 135
  start-page: e12
  year: 2020
  ident: ref_82
  article-title: Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma
  publication-title: World Neurosurg.
  doi: 10.1016/j.wneu.2019.10.044
– volume: 15
  start-page: eadf6724
  year: 2023
  ident: ref_155
  article-title: Immune Checkpoint B7-H3 Is a Therapeutic Vulnerability in Prostate Cancer Harboring PTEN and TP53 Deficiencies
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.adf6724
– volume: 10
  start-page: e2205532
  year: 2023
  ident: ref_79
  article-title: Lipid Nanoparticle Delivery System for mRNA Encoding B7H3-redirected Bispecific Antibody Displays Potent Antitumor Effects on Malignant Tumors
  publication-title: Adv. Sci.
  doi: 10.1002/advs.202205532
– volume: 26
  start-page: 712
  year: 2020
  ident: ref_84
  article-title: Locoregionally Administered B7-H3-Targeted CAR T Cells for Treatment of Atypical Teratoid/Rhabdoid Tumors
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-0821-8
– ident: ref_3
  doi: 10.1186/s12916-016-0623-5
– volume: 5
  start-page: 1052
  year: 2024
  ident: ref_168
  article-title: Role of B7-H3 in Predicting Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer
  publication-title: BJUI Compass
  doi: 10.1002/bco2.418
– ident: ref_6
  doi: 10.3390/ijms221910719
– volume: 21
  start-page: 451
  year: 2024
  ident: ref_2
  article-title: Immune Checkpoint Inhibitors: Breakthroughs in Cancer Treatment
  publication-title: Cancer Biol. Med.
– ident: ref_146
– ident: ref_54
  doi: 10.1038/s41598-021-94360-9
– ident: ref_40
  doi: 10.3389/fimmu.2022.888713
– ident: ref_48
  doi: 10.3390/cancers16112140
– volume: 142
  start-page: 113004
  year: 2024
  ident: ref_165
  article-title: Therapeutic Vaccine Targeting Dual Immune Checkpoints Induces Potent Multifunctional CD8+ T Cell Anti-Tumor Immunity
  publication-title: Int. Immunopharmacol.
  doi: 10.1016/j.intimp.2024.113004
– volume: 133
  start-page: 2050
  year: 2013
  ident: ref_76
  article-title: B7-H3 Associated with Tumor Progression and Epigenetic Regulatory Activity in Cutaneous Melanoma
  publication-title: J. Investig. Dermatol.
  doi: 10.1038/jid.2013.114
– volume: 15
  start-page: eadf6732
  year: 2023
  ident: ref_227
  article-title: Targeting DNA Methylation and B7-H3 in RB1-Deficient and Neuroendocrine Prostate Cancer
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.adf6732
– volume: 22
  start-page: 43
  year: 2023
  ident: ref_7
  article-title: New Frontiers in Immune Checkpoint B7-H3 (CD276) Research and Drug Development
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-023-01751-9
– volume: 13
  start-page: e009544
  year: 2025
  ident: ref_236
  article-title: B7-H3 CAR-T Cell Therapy Combined with Irradiation Is Effective in Targeting Bulk and Radiation-Resistant Chordoma Cancer Cells
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2024-009544
– volume: 4
  start-page: 401
  year: 2018
  ident: ref_11
  article-title: B7-H3 in Cancer–Beyond Immune Regulation
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2018.03.010
– volume: 30
  start-page: 1382
  year: 2023
  ident: ref_154
  article-title: Influence of ADT on B7-H3 Expression during CRPC Progression from Hormone-Naïve Prostate Cancer
  publication-title: Cancer Gene Ther.
  doi: 10.1038/s41417-023-00644-9
– volume: 12
  start-page: 2137
  year: 2020
  ident: ref_125
  article-title: Silencing of CD276 Suppresses Lung Cancer Progression by Regulating Integrin Signaling
  publication-title: J. Thorac. Dis.
  doi: 10.21037/jtd.2020.04.41
– ident: ref_180
  doi: 10.3389/fimmu.2021.744823
– ident: ref_187
– volume: 53
  start-page: 143
  year: 2006
  ident: ref_239
  article-title: B7-H3 and B7-H4 Expression in Non-Small-Cell Lung Cancer
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2006.05.012
– volume: 44
  start-page: 955
  year: 2016
  ident: ref_4
  article-title: Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.05.002
– volume: 21
  start-page: 2199
  year: 2017
  ident: ref_39
  article-title: Selective Blockade of B7-H3 Enhances Antitumour Immune Activity by Reducing Immature Myeloid Cells in Head and Neck Squamous Cell Carcinoma
  publication-title: J. Cell. Mol. Med.
  doi: 10.1111/jcmm.13143
– volume: 41
  start-page: 101874
  year: 2024
  ident: ref_42
  article-title: High Expression of B7-H3 on Monocyte/Macrophages in Tumor Microenvironment Promotes Lung Cancer Progression by Inhibiting Apoptosis
  publication-title: Transl. Oncol.
  doi: 10.1016/j.tranon.2023.101874
– ident: ref_174
  doi: 10.3389/fimmu.2022.818411
– volume: 12
  start-page: 2415577
  year: 2025
  ident: ref_232
  article-title: Reprogramming the Tumor Immune Microenvironment with ICAM-1-Targeted Antibody—Drug Conjugates and B7-H3-CD3 Bispecific Antibodies
  publication-title: Adv. Sci.
  doi: 10.1002/advs.202415577
– volume: 70
  start-page: 2453
  year: 2021
  ident: ref_94
  article-title: Interleukin-7-Loaded Oncolytic Adenovirus Improves CAR-T Cell Therapy for Glioblastoma
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-021-02856-0
– volume: 2
  start-page: 269
  year: 2001
  ident: ref_8
  article-title: B7-H3: A Costimulatory Molecule for T Cell Activation and IFN-γ Production
  publication-title: Nat. Immunol.
  doi: 10.1038/85339
– ident: ref_111
  doi: 10.3390/ijms21197050
– volume: 176
  start-page: 1
  year: 2024
  ident: ref_159
  article-title: Preclinical Assessment of the Efficacy of B7-H3 CAR-T in Renal Cell Carcinoma
  publication-title: Mol. Immunol.
  doi: 10.1016/j.molimm.2024.10.006
– ident: ref_211
  doi: 10.1016/j.bbcan.2021.188636
– volume: 67
  start-page: 7893
  year: 2007
  ident: ref_152
  article-title: B7-H3 Ligand Expression by Prostate Cancer: A Novel Marker of Prognosis and Potential Target for Therapy
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-07-1068
– volume: 371
  start-page: 222
  year: 2018
  ident: ref_151
  article-title: Negative Roles of B7-H3 and B7-H4 in the Microenvironment of Cervical Cancer
  publication-title: Exp. Cell Res.
  doi: 10.1016/j.yexcr.2018.08.014
– volume: 24
  start-page: 331
  year: 2025
  ident: ref_233
  article-title: A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-Cell Engager Immunotherapies
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-24-0327
– volume: 7
  start-page: 1010
  year: 2021
  ident: ref_33
  article-title: Immunity beyond Cancer Cells: Perspective from Tumor Tissue
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2021.06.007
– volume: 28
  start-page: 1621
  year: 2013
  ident: ref_56
  article-title: Dendritic and Lymphocytic Cell Infiltration in Prostate Carcinoma
  publication-title: Histol. Histopathol.
– ident: ref_220
– volume: 30
  start-page: 3243
  year: 2024
  ident: ref_80
  article-title: Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-24-0071
– ident: ref_219
– volume: 38
  start-page: 4283
  year: 2020
  ident: ref_223
  article-title: B7H3-Directed Intraperitoneal Radioimmunotherapy with Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.20.01974
– volume: 257
  start-page: 115489
  year: 2023
  ident: ref_96
  article-title: Development of a MMAE-Based Antibody-Drug Conjugate Targeting B7-H3 for Glioblastoma
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2023.115489
– ident: ref_86
  doi: 10.7150/ijbs.85813
– volume: 26
  start-page: 2140
  year: 2020
  ident: ref_135
  article-title: Efficacy of Affibody-Based Ultrasound Molecular Imaging of Vascular B7-H3 for Breast Cancer Detection
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-19-1655
– volume: 130
  start-page: 2295
  year: 2017
  ident: ref_194
  article-title: Kinetics and Biomarkers of Severe Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor–Modified T-Cell Therapy
  publication-title: Blood
  doi: 10.1182/blood-2017-06-793141
– ident: ref_110
  doi: 10.3389/fimmu.2023.1062856
– volume: 12
  start-page: e009221
  year: 2024
  ident: ref_226
  article-title: Directing B7-H3 Chimeric Antigen Receptor T Cell Homing through IL-8 Induces Potent Antitumor Activity against Pediatric Sarcoma
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2024-009221
– ident: ref_240
  doi: 10.3389/fimmu.2020.00681
– ident: ref_50
  doi: 10.3390/vaccines12010054
– volume: 7
  start-page: eaax3160
  year: 2021
  ident: ref_234
  article-title: B7-H3×4-1BB Bispecific Antibody Augments Antitumor Immunity by Enhancing Terminally Differentiated CD8+ Tumor-Infiltrating Lymphocytes
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.aax3160
– volume: 21
  start-page: 587
  year: 2021
  ident: ref_215
  article-title: B7-H3 Targeted Antibody-Based Immunotherapy of Malignant Diseases
  publication-title: Expert. Opin. Biol. Ther.
  doi: 10.1080/14712598.2021.1862791
– volume: 18
  start-page: 3834
  year: 2012
  ident: ref_210
  article-title: Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-12-0715
– volume: 366
  start-page: 2455
  year: 2012
  ident: ref_216
  article-title: Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1200694
– volume: 15
  start-page: 2338
  year: 2025
  ident: ref_229
  article-title: Histone Lactylation-Driven B7-H3 Expression Promotes Tumor Immune Evasion
  publication-title: Theranostics
  doi: 10.7150/thno.105947
– ident: ref_238
  doi: 10.3390/cancers15123136
– volume: 154
  start-page: 582
  year: 2018
  ident: ref_36
  article-title: The Opposing Roles of CD4+ T Cells in Anti-tumour Immunity
  publication-title: Immunology
  doi: 10.1111/imm.12941
– volume: 38
  start-page: 2426
  year: 2017
  ident: ref_65
  article-title: B7-H3 Is Related to Tumor Progression in Ovarian Cancer
  publication-title: Oncol. Rep.
  doi: 10.3892/or.2017.5858
– volume: 31
  start-page: 134
  year: 2023
  ident: ref_92
  article-title: CXCL11-Armed Oncolytic Adenoviruses Enhance CAR-T Cell Therapeutic Efficacy and Reprogram Tumor Microenvironment in Glioblastoma
  publication-title: Mol. Ther.
  doi: 10.1016/j.ymthe.2022.08.021
– volume: 7
  start-page: 81750
  year: 2016
  ident: ref_120
  article-title: Overexpression of B7-H3 Correlates with Aggressive Clinicopathological Characteristics in Non-Small Cell Lung Cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.13177
– volume: 38
  start-page: 1836
  year: 2020
  ident: ref_101
  article-title: Targets and Antibody Formats for Immunotherapy of Neuroblastoma
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.19.01410
– volume: 39
  start-page: 101801
  year: 2023
  ident: ref_130
  article-title: B7-H3/CD276 and Small-Cell Lung Cancer: What’s New?
  publication-title: Transl. Oncol.
  doi: 10.1016/j.tranon.2023.101801
– volume: 27
  start-page: 3141
  year: 2021
  ident: ref_181
  article-title: Preclinical Evaluation of B7-H3-Specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-20-2540
– ident: ref_171
  doi: 10.3390/ijms25137334
– volume: 33
  start-page: 463
  year: 2018
  ident: ref_38
  article-title: Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.01.011
– ident: ref_71
  doi: 10.1038/s42003-023-05736-8
– ident: ref_133
  doi: 10.1177/1010428318815032
– ident: ref_202
– ident: ref_52
– volume: 18
  start-page: 31
  year: 2023
  ident: ref_126
  article-title: SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2022.10.002
– volume: 168
  start-page: 6294
  year: 2002
  ident: ref_9
  article-title: Characterization of Mouse and Human B7-H3 Genes1
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.168.12.6294
– volume: 25
  start-page: 79
  year: 2022
  ident: ref_70
  article-title: B7-H3 Promotes the Epithelial-mesenchymal Transition of NSCLC by Targeting SIRT1 through the PI3K/AKT Pathway
  publication-title: Mol. Med. Rep.
  doi: 10.3892/mmr.2022.12595
– volume: 17
  start-page: 227
  year: 2020
  ident: ref_29
  article-title: Tumor-Expressed B7-H3 Mediates the Inhibition of Antitumor T-Cell Functions in Ovarian Cancer Insensitive to PD-1 Blockade Therapy
  publication-title: Cell Mol. Immunol.
  doi: 10.1038/s41423-019-0305-2
– volume: 9
  start-page: 447
  year: 2013
  ident: ref_115
  article-title: Paediatrics: Surgical Strategy and Quality of Life in Craniopharyngioma
  publication-title: Nat. Rev. Endocrinol.
  doi: 10.1038/nrendo.2013.125
– volume: 12
  start-page: e009710
  year: 2024
  ident: ref_179
  article-title: Novel Bispecific Antibody-Drug Conjugate Targeting PD-L1 and B7-H3 Enhances Antitumor Efficacy and Promotes Immune-Mediated Antitumor Responses
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2024-009710
– volume: 83
  start-page: 224
  year: 2023
  ident: ref_153
  article-title: B7-H3 as a Therapeutic Target in Advanced Prostate Cancer
  publication-title: Eur. Urol.
  doi: 10.1016/j.eururo.2022.09.004
– volume: 73
  start-page: 98
  year: 2024
  ident: ref_93
  article-title: Incorporating IL7 Receptor Alpha Signaling in the Endodomain of B7H3-Targeting Chimeric Antigen Receptor T Cells Mediates Antitumor Activity in Glioblastoma
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-024-03685-7
– volume: 12
  start-page: 2672
  year: 2021
  ident: ref_141
  article-title: FUT8-Mediated Aberrant N-Glycosylation of B7H3 Suppresses the Immune Response in Triple-Negative Breast Cancer
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-22618-x
– volume: 23
  start-page: 990
  year: 2021
  ident: ref_98
  article-title: Epidemiology of Brainstem High-Grade Gliomas in Children and Adolescents in the United States, 2000–2017
  publication-title: Neuro-Oncology
  doi: 10.1093/neuonc/noaa295
– volume: 30
  start-page: 467
  year: 2017
  ident: ref_77
  article-title: Immunoregulatory Protein B7-H3 Promotes Growth and Decreases Sensitivity to Therapy in Metastatic Melanoma Cells
  publication-title: Pigment. Cell Melanoma Res.
  doi: 10.1111/pcmr.12599
– volume: 35
  start-page: 1
  year: 2016
  ident: ref_221
  article-title: Anti-B7-H3 Monoclonal Antibody Ameliorates the Damage of Acute Experimental Pancreatitis by Attenuating the Inflammatory Response
  publication-title: Int. Immunopharmacol.
  doi: 10.1016/j.intimp.2016.03.013
– volume: 11
  start-page: 7021
  year: 2019
  ident: ref_15
  article-title: Relationship of B7-H3 Expression in Tumor Cells and Tumor Vasculature with FOXP3+ Regulatory T Cells in Renal Cell Carcinoma
  publication-title: CMAR
  doi: 10.2147/CMAR.S209205
– volume: 12
  start-page: e009110
  year: 2024
  ident: ref_192
  article-title: Preclinical Evaluation of Antigen-Sensitive B7-H3-Targeting Nanobody-Based CAR-T Cells in Glioblastoma Cautions for on-Target, off-Tumor Toxicity
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2024-009110
– volume: 28
  start-page: 1597
  year: 2021
  ident: ref_21
  article-title: CD276 Expression Enables Squamous Cell Carcinoma Stem Cells to Evade Immune Surveillance
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2021.04.011
– ident: ref_201
– volume: 8
  start-page: 71725
  year: 2017
  ident: ref_64
  article-title: B7-H3 Promotes Gastric Cancer Cell Migration and Invasion
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.17847
– ident: ref_218
– volume: 4
  start-page: 1369
  year: 2024
  ident: ref_25
  article-title: Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
  publication-title: Cancer Res. Commun.
  doi: 10.1158/2767-9764.CRC-23-0546
– volume: 224
  start-page: 153461
  year: 2021
  ident: ref_138
  article-title: B7-H3 on Breast Cancer Cell MCF7 Inhibits IFN-γ Release from Tumour-Infiltrating T Cells
  publication-title: Pathol. Res. Pract.
  doi: 10.1016/j.prp.2021.153461
– ident: ref_169
  doi: 10.1371/journal.pone.0243379
– volume: 24
  start-page: 2653
  year: 2018
  ident: ref_119
  article-title: Immunotherapy in Non-Small Cell Lung Cancer: Steps towards More Effective Combination Therapies
  publication-title: Transl. Cancer Res.
– volume: 8
  start-page: e000406
  year: 2020
  ident: ref_117
  article-title: Expression and Clinical Significance of PD-L1, B7-H3, B7-H4 and VISTA in Craniopharyngioma
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2019-000406
– volume: 23
  start-page: 999
  year: 2021
  ident: ref_182
  article-title: Cell-Surface Antigen Profiling of Pediatric Brain Tumors: B7-H3 Is Consistently Expressed and Can Be Targeted via Local or Systemic CAR T-Cell Delivery
  publication-title: Neuro-Oncol.
  doi: 10.1093/neuonc/noaa278
– volume: 57
  start-page: 223
  year: 2024
  ident: ref_5
  article-title: The B7:CD28 Family and Friends: Unraveling Coinhibitory Interactions
  publication-title: Immunity
  doi: 10.1016/j.immuni.2024.01.013
– volume: 193
  start-page: 405
  year: 2022
  ident: ref_143
  article-title: B7 Homolog 3 Induces Lung Metastasis of Breast Cancer through Raf/MEK/ERK Axis
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-022-06520-8
– volume: 7
  start-page: e1461304
  year: 2018
  ident: ref_60
  article-title: Large-Scale Analysis Reveals the Specific Clinical and Immune Features of B7-H3 in Glioma
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2018.1461304
– ident: ref_186
– volume: 12
  start-page: 5455
  year: 2015
  ident: ref_242
  article-title: B7-H3 Promotes Cell Migration and Invasion through the Jak2/Stat3/MMP9 Signaling Pathway in Colorectal Cancer
  publication-title: Mol. Med. Rep.
  doi: 10.3892/mmr.2015.4050
– volume: 47
  start-page: 23
  year: 2017
  ident: ref_224
  article-title: B7-H3-Targeted 212Pb Radioimmunotherapy of Ovarian Cancer in Preclinical Models
  publication-title: Nucl. Med. Biol.
  doi: 10.1016/j.nucmedbio.2017.01.003
– volume: 130
  start-page: 363
  year: 2010
  ident: ref_18
  article-title: Enhancement of Effector CD8+ T-Cell Function by Tumour-Associated B7-H3 and Modulation of Its Counter-Receptor Triggering Receptor Expressed on Myeloid Cell-like Transcript 2 at Tumour Sites
  publication-title: Immunology
  doi: 10.1111/j.1365-2567.2009.03236.x
– volume: 18
  start-page: 36
  year: 2023
  ident: ref_158
  article-title: B7-H3 Expression Is Associated with High PD-L1 Expression in Clear Cell Renal Cell Carcinoma and Predicts Poor Prognosis
  publication-title: Diagn. Pathol.
  doi: 10.1186/s13000-023-01320-0
– volume: 13
  start-page: 114
  year: 2023
  ident: ref_100
  article-title: Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-22-0750
– volume: 27
  start-page: 1034
  year: 2017
  ident: ref_59
  article-title: Inhibition of the B7-H3 Immune Checkpoint Limits Tumor Growth by Enhancing Cytotoxic Lymphocyte Function
  publication-title: Cell Res.
  doi: 10.1038/cr.2017.90
– volume: 53
  start-page: 73
  year: 2008
  ident: ref_85
  article-title: Small Round Blue Cell Tumours: Diagnostic and Prognostic Usefulness of the Expression of B7-H3 Surface Molecule
  publication-title: Histopathology
  doi: 10.1111/j.1365-2559.2008.03070.x
– volume: 13
  start-page: 2215
  year: 2020
  ident: ref_66
  article-title: B7-H3 Regulates Glioma Growth and Cell Invasion Through a JAK2/STAT3/Slug-Dependent Signaling Pathway
  publication-title: Onco Targets Ther.
  doi: 10.2147/OTT.S237841
– ident: ref_129
  doi: 10.1016/j.bbrep.2021.101089
– ident: ref_147
– ident: ref_127
  doi: 10.3389/fonc.2021.600238
– volume: 8
  start-page: 865
  year: 1997
  ident: ref_109
  article-title: Second Cancers after Medulloblastoma: Population-Based Results from the United States and Sweden
  publication-title: Cancer Causes Control
SSID ssj0000816105
Score 2.3106256
SecondaryResourceType review_article
Snippet In today’s oncology, immunotherapy arises as a potent complement for conventional cancer treatment, allowing for obtaining better patient outcomes. B7-H3...
In today's oncology, immunotherapy arises as a potent complement for conventional cancer treatment, allowing for obtaining better patient outcomes. B7-H3...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 1209
SubjectTerms Animals
B7 Antigens - immunology
B7 Antigens - metabolism
B7-H3 (CD276)
B7-H3 clinical trials
Biological products
Brain cancer
Brain tumors
Cancer
Cancer immunotherapy
Cancer therapies
Care and treatment
Cell growth
Clinical trials
Colorectal cancer
Cytokines
Cytotoxicity
Dendritic cells
Development and progression
Glioblastoma
Gliomas
Humans
immune checkpoint
Immune checkpoint inhibitors
Immune response
Immunology
Immunotherapy
Immunotherapy - methods
Literature reviews
Lung cancer
Lymphocytes
Lymphocytes T
Malignancy
Melanoma
Molecular modelling
Monoclonal antibodies
Neoplasia
Neoplasms - immunology
Neoplasms - therapy
Neuroblastoma
Neuroblasts
Patients
Pituitary
Prognosis
Prostate cancer
Review
solid tumors
Squamous cell carcinoma
T cells
Transcription factors
Tumor necrosis factor-TNF
Tumorigenesis
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NTtwwEB5VSEhcKkr5CQXkShU9RSSOnbW5LSvQtmpRDyBxsxzbEVyyaBcO3HgInpAnYSbOrhL1wIVrPImc-fHMJDPfAPxwsrCVdCKlD2yYoCif6ipzKRplyT2XgXtqcP57WU6vxe8bedMb9UU1YREeODLuxFdC-yC5z6xFfSuskBqfrbzzpbKxcwt9Xi-Zas9ghZFMJiOoZoF5_Ql9B1_kghwcFR_2nFCL1f__idxzScNyyZ7_udiEz13gyMZxw1_gU2i2YD2Oknz6Cldno3RasLuGTUiOc_aLGj-69qqn1-eXf_NZ21W5YLbxbLKcobI4ZWMWfxCwWc2Qnv1ZIS1vw_XF-dVkmnYTE1InONcpZk-BB6vo31k9CrXTFuMP4ajBFFWGkHBE7ry0eF1piydMJTCBrGReuzoPutiBtWbWhD1gpdDKo3uzldai1kXlSpHVXnvMgaRVIYHjJQvNfQTGMJhQEK_NgNcJnBGDV0SEZ91eQCmbTsrmPSkn8JPEY8jqUAbOds0DuFfCrzJjDBwpkhsh5cGAEq3FDZeXAjadtS5MwXHXbWyTwPfVMt1JFWhNmD1Gmhyj3VwksBv1YfVKqOKEVMYTUANNGbzzcKW5u22xvDFwQFeVqf2P4NI32OA0npgqWsoDWHuYP4ZDjJkeqqPWPN4APfkUKg
  priority: 102
  providerName: Directory of Open Access Journals
Title B7-H3 in Cancer Immunotherapy—Prospects and Challenges: A Review of the Literature
URI https://www.ncbi.nlm.nih.gov/pubmed/40801642
https://www.proquest.com/docview/3239022406
https://www.proquest.com/docview/3239119314
https://pubmed.ncbi.nlm.nih.gov/PMC12346708
https://doaj.org/article/db49de52d0aa4003a4595c48dcd68a01
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3LbtQwcAStkLgg3gRKZSQEp6iJY2dtLmh31WpBUFWolXqzHNspvSRl0x564yP4Qr6EmcQbNkLiak-ixPMezwPgrZOFraQTKQXY0EFRPtVV5lJkypJ7LgP3VOD89bhcnYnP5_I8Bty6mFa5kYm9oPatoxj5QcHRO-_1z8erHylNjaLb1ThC4y7soghW6HztLg6PT76NURYaK4EWxNBcs8A3HFA8vMsFKTpKQtxSRn3P_n8l85ZqmqZNbumho4fwIBqQbD5g_BHcCc1juDeMlLx9AqeLWboq2GXDloTPNftEBSCxzOr2989fJ-u2r67smG08W25mqXQf2JwNFwWsrRnCsy9jx-WncHZ0eLpcpXFyQuoE5zpFLyrwYBXdodWzUDtt0Q4RjgpNkXSoI47InZcW15W2KGkqgY5kJfPa1XnQxTPYadomvABWCq08qjlbaS1qXVSuFFnttUdfSFoVEni3OUJzNTTIMOhY0FmbyVknsKADHoGor3W_0K4vTGQT4yuhfZDcZ9aidCmskBopSXnnS2WzPIH3hB5D3Ic4cDYWEeC3Uh8rM0cDkiy6GULuTSCRa9x0e4NgE7m2M39pLIE34zY9SZloTWhvBpgcrd5cJPB8oIfxl5DUqWMZT0BNKGXyz9Od5vJ739MbDQhUWZl6-f_vegX3OQ0gppyVcg92rtc34TVaRdfVfiT9_T6q8AcZ-w2W
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtNAcFSlQnBBvHEpsEg8Tlbt9drxIiGUhFYJTaMKpVJv7np3Db3YbdwK5cZH8B18FF_CjF_EQuLW6-5YWs97ducB8FqHgUpDLVy6YMMAJTauTD3tolBG3PDQckMFzkeLaHoiPp-Gp1vwq62FobTKVidWitoUmu7I9wKO0Xllfz5eXLo0NYpeV9sRGjVbHNr1dwzZyg-zT0jfN5wf7C8nU7eZKuBqwbl0McKw3KqY3peyoc20VGijhaYiTEQrdYsRvjahwvVYKpTCVGCQlYZ-pjPfUvMlVPnbIsBQZgDb4_3F8ZfuVofGWKDHUjfzDPDEe3T_XvqCDCslPW4Yv2pGwL-WYMMU9tM0N-zewT242zisbFRz2H3YsvkDuFWPsFw_hOV46E4Ddp6zCfHPis2o4KQp61r__vHzeFVU1ZwlU7lhk3Z2S_mejVj9MMGKjCE8m3cdnh_ByY3g9DEM8iK3T4FFQsYGzapKpRSZDFIdCS8z0mDsFarYOvC2RWFyUTfkSDCQIVwnPVw7MCYEd0DUR7taKFZfk0YsE5MKaWzIjacUarNAiVAi58ZGmyhWnu_AOyJPQtKONNCqKVrAs1LfrGSEDit5kEOE3O1BopTq_nZL4KTREmXyl6cdeNVt05eU-Zbb4rqG8dHL9oUDT2p-6H4JRYs6pHEH4h6n9P65v5Off6t6iKPDgibSi3f-f66XcHu6PJon89ni8Bnc4TT8mPJlol0YXK2u7XP0yK7SF40YMDi7acn7AxhMSK4
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtNAcFSlAnFBvDEUWCQeJyv2eu14kRBK0kYJLVGEWqk3d727hl7sErdCufERfA2fw5cw4xexkLj1ujuW1vOe3XkAvNJhoNJQC5cu2DBAiY0rU0-7KJQRNzy03FCB86dlND8RH0_D0x341dbCUFplqxMrRW0KTXfkw4BjdF7Zn2HWpEWs9mcfLr65NEGKXlrbcRo1ixzazXcM38r3i32k9WvOZwfH07nbTBhwteBcuhhtWG5VTG9N2chmWiq010JTQSaimDrHCF-bUOF6LBVKZCow4EpDP9OZb6kRE6r_3RFGRd4AdicHy9Xn7oaHRlqg91I39gzw9EO6iy99QUaWEiC3DGE1L-Bfq7BlFvspm1s2cHYHbjfOKxvX3HYXdmx-D27U4yw39-F4MnLnATvP2ZR4ac0WVHzSlHhtfv_4uVoXVWVnyVRu2LSd41K-Y2NWP1KwImMIz466bs8P4ORacPoQBnmR28fAIiFjgyZWpVKKTAapjoSXGWkwDgtVbB1406IwuaibcyQY1BCukx6uHZgQgjsg6qldLRTrL0kjoolJhTQ25MZTCjVboEQokYtjo00UK8934C2RJyHJRxpo1RQw4Fmph1YyRueVvMkRQu71IFFidX-7JXDSaIwy-cvfDrzstulLyoLLbXFVw_jocfvCgUc1P3S_hGJG3dK4A3GPU3r_3N_Jz79W_cTReUFz6cVP_n-uF3ATJS45WiwPn8ItTnOQKXUm2oPB5frKPkPn7DJ93kgBg7PrFrw_XY5M4w
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=B7-H3+in+Cancer+Immunotherapy%E2%80%94Prospects+and+Challenges%3A+A+Review+of+the+Literature&rft.jtitle=Cells+%28Basel%2C+Switzerland%29&rft.au=Mielcarska%2C+Sylwia&rft.au=Kot%2C+Anna&rft.au=Dawidowicz%2C+Miriam&rft.au=Kula%2C+Agnieszka&rft.date=2025-08-06&rft.pub=MDPI&rft.eissn=2073-4409&rft.volume=14&rft.issue=15&rft_id=info:doi/10.3390%2Fcells14151209&rft_id=info%3Apmid%2F40801642&rft.externalDocID=PMC12346708
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2073-4409&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2073-4409&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2073-4409&client=summon